Résumé
CD103+CD8+ tumor-resident memory T cells (TRM) are important components of anti-tumor immunity. However, their role in response to cancer immunotherapy is not fully understood. The protocol describes how to isolate CD8+ T cells and autologous tumor cells from human lung tumors to study the functional activities of CD8+ T cells. Tumors are heterogeneous in terms of the quantity and quality of immune cell types, so the yield of TRM cells depends on the features of the tumor. For complete details on the use and execution of this protocol, please refer to Corgnac et al. (2020).
langue originale | Anglais |
---|---|
Numéro d'article | 100267 |
journal | STAR Protocols |
Volume | 2 |
Numéro de publication | 1 |
Les DOIs | |
état | Publié - 19 mars 2021 |
Modification externe | Oui |